
|Slideshows|March 2, 2016
Neuro News Roundup: Multiple Sclerosis
Author(s)Mark L. Fuerst
Risk factors regarding MS, including genetic research findings and progressive multifocal leukoencephalopathy while taking natalizumab, are discussed.
Advertisement
New recommendations aim to reduce the risk for progressive multifocal leukoencephalopathy (PML) with use of natalizumab in patients with relapsing remitting multiple sclerosis (RRMS). RRMS patients taking natalizumab who seroconvert to high levels of signaling antibodies are at increased risk of PML. In a new finding, seven loci have been added to the list of genuine MS genetic risk factors.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
A Clinical Review of the 2025 Neuromyelitis Optica Spectrum Disorder Guidelines
2
FDA Action Update, December 2025: Acceptance, Approval, and Clearance
3
Phase 2 Subpopulation Data of Vidofludimus Calcium in Progressive Multiple Sclerosis: Robert J. Fox, MD
4
FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment
5




























